Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

08.06.20	Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease (GlobeNewswire)
03.06.20	Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan (GlobeNewswire)
02.06.20	Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma (GlobeNewswire)
02.06.20	European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma (GlobeNewswire)
02.06.20	Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline (GlobeNewswire)
29.05.20	Sanofi announces closing of Regeneron stock sale (GlobeNewswire)
29.05.20	Regeneron : Data On Libtayo Shows Longer Durability, Higher Complete Response Rates In Skin Cancer (RTTNews)
29.05.20	Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time (GlobeNewswire)
29.05.20	Sanofi names new leaders to Executive Committee (GlobeNewswire)
28.05.20	Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director (GlobeNewswire)
27.05.20	Sanofi : FDA Approves Dupixentas To Treat Moderate-to-severe Atopic Dermatitis (RTTNews)
27.05.20	Regeneron Announces Pricing Of Secondary Offering Of Its Stock Held By Sanofi At $515.00/shr (RTTNews)
27.05.20	Sanofi announces pricing of Regeneron stock offering (GlobeNewswire)
26.05.20	Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (GlobeNewswire)
25.05.20	Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration (GlobeNewswire)
23.05.20	Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints (GlobeNewswire)
18.05.20	Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event (GlobeNewswire)
14.05.20	Sanofi: FDA Grants Priority Review Of Sutimlimab - Quick Facts (RTTNews)
14.05.20	FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease (GlobeNewswire)
12.05.20	Sanofi: Sarclisa Trial Meets Primary Goal Early In Relapsed Multiple Myeloma (RTTNews)
12.05.20	Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma (GlobeNewswire)
05.05.20	Sanofi: Libtayo Shows Clinically-Meaningful And Durable Responses In Skin Cancer (RTTNews)
05.05.20	Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma (GlobeNewswire)
28.04.20	Sanofi: Annual General Meeting of April 28, 2020 (GlobeNewswire)
28.04.20	Biotech Stocks Facing FDA Decision In May 2020 (RTTNews)
27.04.20	Regeneron, Sanofi To Amend Trial To Enroll Only Critical COVID-19 Patients (RTTNews)
27.04.20	Regeneron, Sanofi: Libtayo Meets Primary Endpoint In Phase 3 Trial (RTTNews)
27.04.20	Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival (GlobeNewswire)
27.04.20	Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients (GlobeNewswire)
24.04.20	Sanofi Q1 Profit Climbs; Backs FY20 Earnings Growth View (RTTNews)
24.04.20	Sanofi : FDA Approves MenQuadfi Meningococcal Conjugate Vaccine (RTTNews)
24.04.20	FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination (GlobeNewswire)
23.04.20	Sanofi Reports Encouraging Results From Phase 2b Study With BTK Inhibitor (RTTNews)
23.04.20	Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis (GlobeNewswire)
17.04.20	Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis (GlobeNewswire)
16.04.20	Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution (GlobeNewswire)
14.04.20	Sanofi, GSK To Jointly Develop Adjuvanted Vaccine For COVID-19 (RTTNews)
14.04.20	Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 (GlobeNewswire)
10.04.20	Sanofi To Donate 100 Mln Doses Of Hydroxychloroquine To 50 Countries (RTTNews)
10.04.20	COVID-19: Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries (GlobeNewswire)
06.04.20	Sanofi finalizes Praluent® (alirocumab) restructuring with Regeneron (GlobeNewswire)
06.04.20	Sanofi successfully prices taps on outstanding bond issues for EUR 500 million (GlobeNewswire)
06.04.20	New Drugs Approved In The Month Of March (RTTNews)
03.04.20	Sanofi: Availability of the Pre-quarterly Results Communication (GlobeNewswire)
03.04.20	Regeneron, Sanofi Announce Detailed Positive Results From Dupixent Trial (RTTNews)
03.04.20	Sanofi: Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years (GlobeNewswire)
02.04.20	FDA Recalls Sanofi's Zantac Heartburn Drug, All Generics (RTTNews)
01.04.20	Sanofi: Information on Sanofi’s Shareholder General Meeting of Tuesday, April 28, 2020 (GlobeNewswire)
30.03.20	Regeneron, Sanofi Begin COVID-19 Clinical Program Outside Of U.S. (RTTNews)
30.03.20	Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

21.11.24		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
21.11.24		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
21.11.24		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
21.11.24		SDAX aktuell: SDAX zum Handelsende auf grünem Terrain
21.11.24		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen
21.11.24		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
21.11.24		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
21.11.24		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus

21.11.24

Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone

21.11.24

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

21.11.24

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

21.11.24

SDAX aktuell: SDAX zum Handelsende auf grünem Terrain

21.11.24

Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen

21.11.24

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone